Drug Trial Radar · NCT00889382
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Aug 5, 2009
Primary completion
Aug 1, 2014
Study completion Aug 25, 2014
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Apr 28, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.
Conditions
- Ovarian Cancer
- Solid Tumors
Interventions
OSI-906Drug
Administered orally
PaclitaxelDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Time frame: 28 days
- Progression Free Survival (PFS)Time frame: 36 months
Locations
46 sites in 10 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
Department of Obstetrics and Gynecology, University of California, Irvine
Orange, California
Horizon Oncology Center
Lafayette, Indiana
Ochsner Clinic Foundation
New Orleans, Louisiana
Morristown Memorial Hospital
Morristown, New Jersey
Blumenthal Cancer Center - Main
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
WestMead Hospital
Westmead, New South Wales, Australia
Mater Adult Hospital
South Brisbane, Queensland, Australia
Royal Adelaide Hospital
North Terrace, South Australia, Australia
Launceston General Hospital
Launceston, Tasmania, Australia
Frankston Hospital
Frankston, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
St. John of God Hospital, Bunbury
Bunbury, Western Australia, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
St. John of Gog Hospital, Subiaco
Subiaco, Western Australia, Australia
Juravinski Cancer Center
Hamilton, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
McGill University
Montreal, Quebec, Canada
University Hospital Hradec Kralove
Kralove, Czechia
University Hospital Ostrava
Ostrava- Poruba, Czechia
General University Hospital, Department of Obstetrics and Gynecology
Prague, Czechia
Universitaria di Bologna Policlinico
Bologna, Italy
Ospedale di Carpi, AUSL di Modena
Carpi, Italy
Instituto Europeo di Oncologia
Milan, Italy
Oncology IDI- IRCSS
Roma, Italy
III Oddzial Onkologii Ginekologicznej
Lublin, Poland
Oddzial Radioterapii
Poznan, Poland
Klinika Onkologii AM w Poznaniu
Poznan, Poland
Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala
Cluj-Napoca, Romania
Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia Radiologie
Cluj-Napoca, Romania
Oncology Medical Centre SCM
Iași, Romania
Clinical Caunty Hospital Mures
Mures, Romania
Central Clinical Hospital
Moscow, Russia
Moscow City Oncology Hospital
Moscow, Russia
State Institution Medical Radiology Scientific Center
Obninsk, Russia
Sity Clinical Oncology
Saint Petersburg, Russia
Ospedale San Giovanni
Bellinzona, Switzerland
Royal Marsden Hospital
London, United Kingdom
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.